Project #70: Combined inhibition of RANKL/RANK and DYRK1A pathways for T1D therapy
Forecasted
Project #70, funded by Diabetes Research Connection, explores combined RANKL/RANK and DYRK1A inhibition to promote beta cell regeneration and new therapies for type 1 diabetes.
Funder: Diabetes Research Connection
Due Dates (Anticipated): July 2027 (application open & deadline, projected)
Funding Amounts: Up to $75,000 per project for one year; graduate students eligible for up to $50,000, postdocs/assistant professors up to $75,000.
Summary: Funds innovative, early-stage research by early-career scientists focused on regenerating and protecting pancreatic beta cells in type 1 diabetes.
Key Information: For U.S.-based early-career researchers only; strong focus on innovation and translational potential in T1D.
Description
This Diabetes Research Connection (DRC) grant supports innovative research projects aimed at advancing therapies for type 1 diabetes (T1D), specifically by targeting beta cell regeneration, survival, and function. Project #70 focuses on a combined therapeutic approach inhibiting both the RANKL/RANK and DYRK1A pathways, leveraging molecules already in clinical trials to maximize translational potential. The DRC’s broader funding program is designed to empower early-career scientists in the U.S. to pursue novel, peer-reviewed research that could lead to breakthroughs in T1D treatment, prevention, or management.
